1 month Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics Investor's Business Daily
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
The post Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics appeared first on Investor's …